Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ilumya Generic Name & Formulations
Legal Class
Rx
General Description
Tildrakizumab-asmn 100mg/mL; soln for SC inj; preservative-free.
Pharmacological Class
Interleukin-23 antagonist.
How Supplied
Single-dose prefilled syringe—1 (w. needle guard + cover)
Manufacturer
Generic Availability
NO
Ilumya Indications
Indications
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Ilumya Dosage and Administration
Adult
Give by SC inj in abdomen, thighs, or upper arm. ≥18yrs: 100mg at Weeks 0 and 4, then every 12 weeks thereafter.
Children
<18yrs: not established.
Administration
Do not administer 2 inches around the navel or in areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, avoid scars, stretch marks, blood vessels.
Nursing Considerations
Do not administer 2 inches around the navel or in areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis. Also, avoid scars, stretch marks, blood vessels.
Ilumya Contraindications
Not Applicable
Ilumya Boxed Warnings
Not Applicable
Ilumya Warnings/Precautions
Warnings/Precautions
Should only be administered by a healthcare provider. Discontinue if serious hypersensitivity reaction occurs; treat appropriately. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for tuberculosis (TB) infection prior to initiating. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.
Ilumya Pharmacokinetics
Absorption
Absolute bioavailability: 73–80%. Maximum peak concentration reached: ~6 days.
Distribution
Volume of distribution: 10.8 L.
Elimination
Half-life: ~23 days. Systemic clearance: 0.32 L/day.
Ilumya Interactions
Interactions
Concomitant live vaccines: not recommended.
Ilumya Adverse Reactions
Adverse Reactions
Upper respiratory infections, inj site reactions, diarrhea; hypersensitivity reactions.
Ilumya Clinical Trials
See Literature
Ilumya Note
Not Applicable
Ilumya Patient Counseling
See Literature
